New Vaccine Could Help People With Multiple Food Allergies

Resumen detallado
A new approach to food allergies showed promising results in early tests, and researchers are preparing for human trials.
Researchers in Denmark have developed a new vaccine designed to protect against multiple food allergies with a single treatment.
The experimental vaccine has shown promising results in mice, stimulating the production of protective antibodies against several related food allergens. The team is now refining the technology and preparing for human trials.
More than 220 million people worldwide suffer from food allergies, according to United Nations figures. These allergies occur when the immune system perceives otherwise harmless food proteins as dangerous, triggering reactions that can range from vomiting and a runny nose to potentially life-threatening anaphylaxis.
Current treatment options include exposing patients to increasing amounts of the allergen over several years, using injections or tablets, to help the immune system develop tolerance. However, the process can be uncomfortable and time-consuming, leading many people to avoid the foods that trigger their allergies.
As an alternative, researchers at the Technical University of Denmark (DTU) have developed a vaccine containing a synthetic allergen, designed to target several related allergens found in foods such as peaches and certain nuts.
“The idea is that if you are allergic to several different things, all of which have roughly the same molecular structure, we can take this structure and produce an artificial allergen, which we then incorporate into a vaccine,” explains Associate Professor Esperanza Rivera de Torre from DTU Bioengineering.
The vaccine uses messenger RNA (mRNA), the technology also used in COVID-19 vaccines, which rather than exposing patients directly to the allergen, gives the body instructions to produce protective antibodies that recognize and block the allergens before they trigger a reaction.
This approach could potentially help people who react to several foods containing structurally similar allergens.
"We use the mRNA as a Trojan horse," said Rivera de Torre.
Inicio del artículo, extracto de Newsweek. Para leer el resto, abra el artículo en el sitio del medio.
MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.newsweek.com)

